Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Autor: | Kenneth Robertson, Zoran Gucev, Johnny Ludvigsson, L. Mordhorst, M. A. Gall, E Schoenle |
---|---|
Rok vydání: | 2007 |
Předmět: |
Male
medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Isophane NPH insulin Hypoglycemia Insulin aspart Endocrinology Insulin Detemir Risk Factors Diabetes mellitus Internal medicine Internal Medicine Humans Hypoglycemic Agents Insulin Medicine Child Pancreatic hormone Insulin detemir Type 1 diabetes Dose-Response Relationship Drug business.industry nutritional and metabolic diseases Glucose Tolerance Test medicine.disease Insulin Long-Acting Diabetes Mellitus Type 1 Female business hormones hormone substitutes and hormone antagonists medicine.drug |
Zdroj: | Diabetic Medicine. 24:27-34 |
ISSN: | 1464-5491 0742-3071 |
Popis: | Aims This study compared the effect of insulin detemir on glycaemic control (HbA1c, fasting plasma glucose and variability thereof) with that of Neutral Protamine Hagedorn human isophane (NPH) insulin, both combined with insulin aspart, in children with Type 1 diabetes mellitus, and compared the safety of these treatments. Methods In this 26-week, open-label, randomized (2 : 1), parallel-group study, 347 (140 prepubertal and 207 pubertal) children with Type 1 diabetes, aged 6–17 years, received insulin detemir (n = 232) or NPH insulin (n = 115) once or twice daily, according to the prestudy regimen, plus premeal insulin aspart. Results The mean HbA1c decreased by ∼0.8% with both treatments. After 26 weeks, the mean difference in HbA1c was 0.1% (95% confidence interval −0.1, 0.3) (insulin detemir 8.0%, NPH insulin 7.9%). Within-subject variation in self-measured fasting plasma glucose was significantly lower with insulin detemir than with NPH insulin (SD 3.3 vs. 4.3, P |
Databáze: | OpenAIRE |
Externí odkaz: |